Tag: <span>GSK’s BENLYSTA</span>

Home / GSK’s BENLYSTA
Post

DA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US

Approval builds on nearly 10 years of experience in lupus GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus...